New Hereditary Angioedema Treatment Data to be Presented
The data release will provide new insights for those managing hereditary angioedema and their doctors.
Updated on Oct. 29, 2026 in Allergies
Live Poll
Do you believe upcoming clinical trial results will provide better treatment options for your health needs?
Pharvaris will present new Phase 3 trial and real-world data at the upcoming American College of Allergy, Asthma & Immunology 2026 Annual Scientific Meeting in Phoenix. The meeting, scheduled for November 12-16, 2026, will feature one oral presentation and five poster presentations from the company.
Why it matters
The upcoming data presentations provide insight into the efficacy and safety profile of deucrictibant, offering researchers and clinicians new findings on treatment options for hereditary angioedema. These results may inform future clinical approaches to managing this rare condition.
The upcoming findings include data from the Phase 3 CHAPTER-3 trial alongside real-world evidence for deucrictibant. Researchers will share one late-breaking oral presentation and five poster sessions, though final trial outcomes remain pending until the meeting occurs.
The players
Pharvaris
A biopharmaceutical company developing oral treatments for bradykinin-mediated diseases like hereditary angioedema.
American College of Allergy, Asthma & Immunology
A professional medical association that advances the specialty of allergy and immunology through research and education.
The details
The presentations focus on deucrictibant, an investigational oral treatment designed for hereditary angioedema. By examining data from the Phase 3 CHAPTER-3 study, clinicians are investigating how this extended-release tablet interacts with the biological pathways involved in swelling attacks. The session will also highlight findings from the CHAPTER-1 extension study and evaluations of the economic burden associated with the condition.
Timeline
November 12-16, 2026: The ACAAI 2026 Annual Scientific Meeting occurs in Phoenix.
November 13, 2026: The deucrictibant immediate-release capsule poster presentation takes place.
November 14, 2026: Presentations regarding the economic burden of hereditary angioedema and the CHAPTER-3 trial occur.
November 15, 2026: Poster presentations regarding the CHAPTER-1 extension and safety evaluations are scheduled.
Health Landscape
The findings represent a significant update within the broader CHAPTER clinical trial program for hereditary angioedema. These presentations reflect the ongoing effort to transition toward oral, extended-release therapies from existing standards of care.
These presentations provide new data that may change how specialists approach treatment plans for hereditary angioedema patients. If you or a family member manage this condition, discussing these emerging findings with your primary care provider or specialist is a helpful way to stay informed.
The takeaway
New research into oral therapies for hereditary angioedema continues to evolve as clinical trial data matures. Patients should track updates on these treatments and consult their physician to see how new evidence might influence future care options.
What happens next
The presentations are scheduled to take place at the ACAAI 2026 Annual Scientific Meeting in Phoenix between November 12 and November 16, 2026.
Further reading
For more on managing hereditary conditions, visit Allergies.
More information
View full presentation details at the Pharvaris events and presentations portal.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe upcoming clinical trial results will provide better treatment options for your health needs?
